Open Questions Known risks: clinical, competitive, regulatory, reimbursement, IP, financial, commercial, pricing Assumptions GLP-1 sales for 2023 were approximately $29 billion and it is estimated that 30% of prescriptions could not be filled due to shortages

More serious but less common adverse effects require clinical vigilance: Pancreatitis : Patients should be counselled to stop the medication and seek immediate medical attention if they experience severe, persistent abdominal pain radiating to the back [1] [5] Gallbladder disease : Rapid weight loss associated with GLP-1 therapy may increase cholelithiasis risk [1] Hypoglycaemia : Particularly when used alongside insulin or sulphonylureas in diabetes management Diabetic retinopathy : Semaglutide requires caution in patients with pre-existing retinopathy, who should be monitored regularly [1] Renal impairment : Dehydration from gastrointestinal side effects may affect kidney function Specific considerations for individuals with eating disorders include the potential for GLP-1 medications to exacerbate restrictive eating patterns or mask hunger cues in vulnerable individuals

While natural approaches to raising GLP-1 are not as potent as medications, they provide a drug-free approach to weight loss and healthy eating
Then, after 3 hours, we found moderate lesions, and finally, after 24 hours severe lesions ( Table 1, Fig
Emerging evidence now shows addiction isnt exclusively a disorder of synapses and dopamine